SCHEMBL3707258

SCHEMBL3707258

Cc1ccnc2c(-c3ccccc3)c(NC(=O)Cc3ccccc3)nn12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 1/20 0.48
TMIGD3 P0DMS9 1/20 0.48
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
RAB9A P51151 2/20 0.46
NPC1 O15118 1/20 0.46
WNT3A P56704 3/20 0.45
KCNQ3 O43525 2/20 0.44
KCNQ2 O43526 2/20 0.44
HPGD P15428 1/20 0.44
LMNA P02545 1/20 0.43
HTT P42858 1/20 0.43
HTR6 P50406 1/20 0.43
SLC6A2 P23975 1/20 0.43
SLC6A3 Q01959 1/20 0.43
ADORA3 P0DMS8 2/20 0.42
ADORA1 P30542 2/20 0.42
ADORA2A P29274 1/20 0.42
ADORA2B P29275 1/20 0.42
MAPT P10636 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3701916 0.87 MAPK14 (0.52) MAPK14KMT2ARAB9ANPC1WNT3A
SCHEMBL3710474 0.80 HCAR2 (0.47) MAPK14MEN1KMT2ARAB9ANPC1
SCHEMBL3696615 0.80 ALDH1A1 (0.46) WNT3ALMNAHTTADORA3
SCHEMBL3706811 0.80 MAPT (0.43) MAPK14WNT3AKCNQ3KCNQ2HPGD
SCHEMBL3707943 0.79 KCNQ3 (0.43) MAPK14KMT2ARAB9ANPC1WNT3A
SCHEMBL3706555 0.79 KCNQ3 (0.49) MEN1KMT2AWNT3AKCNQ3KCNQ2
SCHEMBL3709636 0.79 KCNQ3 (0.53) MAPK14MEN1KMT2AWNT3AKCNQ3
SCHEMBL3695035 0.77 KCNQ3 (0.55) MAPK14MEN1KMT2ARAB9ANPC1
SCHEMBL3695805 0.76 ALDH1A1 (0.46) MEN1KMT2AWNT3AKCNQ3KCNQ2
SCHEMBL3701012 0.75 KCNQ3 (0.56) NPC1KCNQ3KCNQ2HPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8609669-B2 Potassium channel modulators ABBVIE INC. (US) 2013-12-17 US claimed
WO-2012067822-A1 PYRAZOLO [1, 5 -A] PYRIMIDIN POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2012-05-24 WO claimed
US-20120122888-A1 Potassium Channel Modulators ABBOTT LABORATORIES (US) 2012-05-17 US claimed
US-8609669-B2 Potassium channel modulators ABBVIE INC. (US) 2013-12-17 US disclosed
WO-2012067822-A1 PYRAZOLO [1, 5 -A] PYRIMIDIN POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2012-05-24 WO disclosed
US-20120122888-A1 Potassium Channel Modulators ABBOTT LABORATORIES (US) 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122888-A1 Potassium Channel Modulators KCNQ1, KCNQ2, KCNJ2 MAPK14 3073/4885TMIGD3 3199/4885MEN1 1516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.